Compositions and methods comprising prostate stem cell antigen (PSCA) chimeric antigen receptors (CARs)
AssigneeThe Trustees of the University of Pennsylvania
InventorYangbing Zhao
Life of this patent
Estimating the term…
Abstract
The present disclosure provides modified immune cells or precursors thereof (e.g. T cells) comprising a chimeric antigen receptor (CAR) capable of binding human PSCA. CARs capable of binding human PSCA, and nucleic acids encoding the same are also provided. Provided herein are bispecific CARs capable of binding human PSCA and human PSMA, nucleic acids encoding the same, and modified immune cells comprising the same. Modified immune cells comprising a PSMA CAR and a PSCA CAR are also provided. Compositions and methods of treatment are also provided.
Claims16
A modified immune cell or precursor cell thereof, comprising a chimeric antigen receptor (CAR) comprising an antigen binding domain capable of binding prostate stem cell antigen (PSCA), a transmembrane domain, and an intracellular domain, wherein the CAR comprises the amino acid sequence of SEQ ID NO:
- 21, 23, 25, or 27.
A modified immune cell or precursor cell thereof, comprising a vector comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising an antigen binding domain capable of binding prostate stem cell antigen (PSCA), a transmembrane domain, and an intracellular domain, wherein the CAR comprises the amino acid sequence of SEQ ID NO:
- 21, 23, 25, or 27.
Dependencies are inferred from the claim text.